Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
LRRFIP2 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, IF, E |
|---|---|
| Primary Accession | Q9Y608 |
| Other Accession | NP_006300, 5453726 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | 82171 Da |
| Application Notes | LRRFIP2 antibody can be used for detection of LRRFIP2 by Western blot at 0.5 and 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL. |
| Gene ID | 9209 |
|---|---|
| Target/Specificity | LRRFIP2; Three isoforms of LRRFIP2 are known to exist; this antibody will recognize all three. LRRFIP2 antibody is predicted to not cross-react with other LRRFIP family members. |
| Reconstitution & Storage | LRRFIP2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | LRRFIP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | LRRFIP2 |
|---|---|
| Function | May function as activator of the canonical Wnt signaling pathway, in association with DVL3, upstream of CTNNB1/beta-catenin. Positively regulates Toll-like receptor (TLR) signaling in response to agonist probably by competing with the negative FLII regulator for MYD88-binding. |
| Tissue Location | Widely expressed, with highest levels in heart and skeletal muscle. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LRRFIP2 Antibody: The leucine-rich repeat FLI-I-interacting protein 2 (LRRFIP2), like the related protein LRRFIP1, was identified in a yeast two-hybrid system through binding to the LRR domain of human FLI. It can activate the Wnt signaling pathway in cultured cells and is thought to be a component of the Wnt signaling pathway that modulates Wnt signaling through interactions with Disheveled to increase the cellular levels and transcription activity of beta-catenin. LRRFIP2 has recently been characterized as a positive regulator of the TLR4 signaling pathway for activating NF-κB during the early host response to LPS stimulation through binding to the TLR adaptor protein MyD88, and that this interaction with MyD88 is governed by phosphorylation of specific residues in LRRFIP2.
References
Fong KS and de Couet HG. Novel proteins interacting with the leucine-rich repeat domain of human flightless-I identified by the yeast two-hybrid system. Genomics 1999; 58:146-57.
Liu J, Bang AG, Kintner C, et al. Identification of the Wnt signaling activator leucine-rich repeat in Flightless interaction protein 2 by a genome-wide functional analysis. Proc. Natl. Acad. Sci. USA 2005; 102:1927-32.
Dai P, Jeong SY, Yu Y, et al. Modulation of TLR signaling by multiple MyD88-interacting including leucine-rich repeat Fli-I-interacting proteins. J. Immunol. 2009; 182:3450-60.
Gunawardena HP, Huang Y, Kenjale R, et al. Unambiguous characterization of site-specific phosphorylation of Leucine-rich FLI-I-interacting protein 2 (LRRFIP2) in Toll-like receptor 4 (TLR4)-mediated signaling. J. Biol. Chem. 2011; epub.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
